Painchek Ltd · ASX:PCK
Painchek — NWR Communications Virtual Health Conference (May 2020)
25 slides from Painchek's conference presentation, May 1, 2020
Slide 1: PainChek to present at NWR Virtual Health Conference
PainChek Limited (ASX: PCK) For personal use only ABN 21 146 035 127 192020 Suite 401, 35 Lime Street, Sydney, NSW, 2000 Phone +61 8 9388 8290 info@painchek.com PainChek to present at NWR Virtual Health Conference 1 May 2020: Listed Australian company PainChek Ltd (ASX:PCK) is pleased to provide an
Slide 2: About PainChek
About PainChek® PainChek® Ltd is an Australian based For personal use only company that develops pain assessment technologies. PainChek® is a smart-phone based medical device using artificial intelligence to assess and score pain levels in real time and update medical records in the cloud. PainChek®
Slide 3: Investor Presentation & Quarterly Update May 2020
® For personal use only Philip Daffas CEO & MD Investor Presentation & Quarterly Update May 2020 PainChek Ltd ASX:PCK 1 PainChek™ Commercial in Confidence
Slide 4: Executive Summary
Executive Summary ▪ PainChek provides Software-As-A-Service that utilizes AI for the detection of patient pain via video analysis For personal use only • Targeting enterprise customers who have patients with an inability to communicate pain levels (ie dementia) • Video assessment via mobile app, ide
Slide 5: March 2020 Quarterly Update
March 2020 Quarterly Update For personal use only ▪ PainChek had its strongest ever quarter delivering 50%+ QOQ growth in all key metrics and its maiden operating positive cashflow quarter ▪ Strong pipeline of sales to continue growth in the June quarter and to reach 100,000 dementia bed target by Q
Slide 6: Growth in Beds & Facilities
Growth in Beds & Facilities For personal use only Total number of contracted clients and RACs across all of our markets Total approved beds contracted in all markets as well as the dementia specific beds (Australia, UK, NZ and Singapore). Total clients and RACs increased 79% and signed under the Gov
Slide 7: Growth in Contracted ARR & Pain Assessments
Growth in Contracted ARR & Pain Assessments For personal use only Contracted ARR for quarters to 30 Sept 2019 were a multiple of MRR x 12 Cumulative number of PainChek assessments conducted globally months. Contracted ARR for the quarters ending 31 Dec 2019 and later are from 1 January 2018 presente
Slide 8: The problem
The problem For personal use only Pain assessment is difficult especially for those who cannot communicate such as dementia sufferers or infants/toddlers. Pain is often under detected. Leading to under treatment and misdiagnosis. This can lead to adverse impact on quality of care, operational effici
Slide 9: Our “Why”
Our “Why” Our purpose is to For personal use only give a voice to people who cannot verbalise their pain 7 PainChek™ Commercial in Confidence
Slide 10: Pain Assessment in dementia is ready for disruption
Pain Assessment in dementia is ready for disruption Abbey Pain PainChek® Abbey Pain Scale and similar manual systems are the current For personal use only ▪ Scale standard of care in developed countries for assessment of pain in dementia patients ▪ Key inputs in the Abbey Pain Scale rely on signific
Slide 11: PainChek - protecting the vulnerable during COVID
PainChek® - protecting the vulnerable during COVID 19 For personal use only Implement Remotely • PainChek® harnesses online communication channels, such as video conferencing, webinars, and email, to roll-out with no need for our team to access aged care facilities. • PainChek® has now released a ro
Slide 12: Dementia Is A Large Market Opportunity
PainChek® - Dementia Is A Large Market Opportunity ▪ 47Million living with dementia globally - estimated to increase to 75 Million by 2025 For personal use only ENTERPRISE DEMENTIA MARKET VALUE Aus UK US ROW est TOTAL No. Aged Care 0.22m 0.54m 1.7m 4.5m 6.96m Beds Annual Market Value @ A$4 per A$11m
Slide 13: PainChek positioned to enter $2bn+ annual Australian home care market
PainChek positioned to enter $2bn+ annual Australian home care market Industry Participants For personal use only Advisory Connectors Service Delivery Putting consumers together with No package management or ownership - Can be split into Financial service providers and building their deliver the cli
Slide 14: Collaboration with Philips Healthcare to enter global hospital market
Collaboration with Philips Healthcare to enter global hospital market • PainChek integration with hospital patient monitoring systems is easy For personal use only and provides value add to existing vital signs • 25-42% of all hospital • Can deliver early beds occupied with warning pain alerts peopl
Slide 15: New Product Development: Pre-verbal Children’s App
New Product Development: Pre-verbal Children’s App • Parents/practitioners have difficulty discerning whether pre-verbal children (0-3 years) are in genuine pain or For personal use only just crying from discomfort, hungry, wanting attention etc. • We have leveraged the same facial recognition techn
Slide 16: Pipeline Of New Product Launches To Support Growth
Pipeline Of New Product Launches To Support Growth Initial Market entry with Enterprise versions to validate utility with Health Care Professionals (HCP) sector and build value For personal use only ▪ ▪ Direct to Carer market expansion when HCP support in place and DTC training materials ▪ 47 Millio
Slide 17: Highlights of PainChek Business and Revenue Model
Highlights of PainChek® Business and Revenue Model ✓ Patent coverage and no direct competition – we have first mover advantage for 15 years+ For personal use only ✓ 80-85%+ gross margins – very low cost of goods sold ✓ Small sales force requirement o Initial enterprise B2B model requires small globa
Slide 18: Diversified customer and partners
Diversified customer and partners For personal use only Example Aged Care Customers Advocates 16 PainChek™ Commercial in Confidence
Slide 19: Integration partners
Integration partners • PainChek is integrated with aged care management systems covering more than 160,000 aged care For personal use only beds in Australia and 40,000 beds in the UK • This means a point of care PainChek assessment on a resident is automatically transmitted to the care management sy
Slide 20: Australian Federal Government Support of $5m – extended to June 2021
Australian Federal Government Support of $5m – extended to June 2021 • Aus Federal govt. has pledged $5m for PainChek to implement into Residential aged care market For personal use only • Government is paying for a 12-month PainChek license subscription for up to 100k beds • Govt wants to aid rapid
Slide 21: THE TEAM
THE TEAM For personal use only Philip Daffas Prof. Jeff Hughes Andrew Hogan CEO & Managing Director, MBA, BSc Chief Scientific Officer PhD, MPS Manager, National Rollout Philip is a highly accomplished global business Jeff is a professor in the School of Pharmacy, Andy is a Psychologist, management
Slide 22: THE BOARD
THE BOARD For personal use only John Murray Chairman John Murray Philip Daffas Ross Harricks Adam Davey Non- Exec Chair CEO & Managing Director Non-Exec Director Non-Exec Director 25 years in tech and Venture Capital. Founder of Technology Venture Philip is a highly accomplished global Senior global
Slide 23: Catalysts and Expected Newsflow
Catalysts and Expected Newsflow For personal use only ✓ Govt contract signed and expansion of Australian customer base – Q4 2019 ✓ First UK sales of Enterprise Dementia product - Q4 2019 ✓ First NZ sales of Enterprise Dementia product - Q4 2019 ✓ FDA de Novo pre-sub supplement completed for Adult pr
Slide 24: PainChek Financial Update
PainChek® Financial Update For personal use only • Shares on issue: 1,035,522,400 • Market cap undiluted at 12c = $124m • Market Cap fully diluted at 12c = $128m • Unlisted Options/PR on issue: 33,547,957 • Fully diluted capital: 1,069,070,357 • Cash at bank @ 31 March‘20: $6.4m 22 PainChek™ Commerc
Slide 25: Investor Presentation & Quarterly Update May 2020
® For personal use only Philip Daffas CEO & MD Investor Presentation & Quarterly Update May 2020 PainChek Ltd ASX:PCK 23 PainChek™ Commercial in Confidence
PainChek — NWR Communications Virtual Health Conference (May 2020) on 6ix